What is TSHA's current stock price?

TSHA (Taysha Gene Therapies, Inc.) is currently trading at $5.49 with a market cap of $1.37B.

What sector is Taysha Gene Therapies, Inc. in?

Taysha Gene Therapies, Inc. (TSHA) operates in the Healthcare sector, specifically in the Biotechnology industry.

Is TSHA a good stock to buy?

Analysts have a Buy consensus on TSHA with a price target of $11.50. Check our detailed analysis for valuation, financials, and insider activity.

InvestLog

TSHA Taysha Gene Therapies, Inc.

Healthcare

$5.49-0.90%ClosedMarket Cap: $1.37B

As of 2026-05-25

Valuation

View Details

P/E (TTM)

—

PEG

—

P/B

9.50

P/S

183.88

EV/EBITDA

-8.56

DCF Value

$0.64

FCF Yield

-8.2%

Div Yield

0.0%

Margins & Returns

Gross Margin

88.2%

Operating Margin

-1774.4%

Net Margin

-1738.4%

ROE

-56.1%

ROA

-43.2%

ROIC

-47.3%

Financials

View All

Period	Revenue	Net Income	EPS
Q1 null	$0.00	$-42.4M	$—
Q4 null	$5.5M	$-27.9M	$—
FY null	$9.8M	$-109.0M	$—
Q3 null	$0.00	$-32.7M	$—

Analyst Ratings

View All

Consensus

Buy

Target (Consensus)

$11.50

Target (Median)

$11.00

Target Range

$11.00 - $13.00

3 Strong Buy11 Buy0 Hold0 Sell0 Strong Sell

Canaccord GenuityBuy

2026-04-06

NeedhamBuy

2026-03-19

Chardan CapitalBuy

2026-03-19

Chardan CapitalBuy

2026-01-06

Wells FargoOverweight

2026-01-05

Trading Activity

Insider Trades

View All

Nagendran Sukumardirector, officer: President and Head of R&D

SellMon Apr 13

Nagendran Sukumardirector, officer: President and Head of R&D

SellMon Apr 13

Alam Kamranofficer: CHIEF FINANCIAL OFFICER

SellFri Feb 06

Nolan Sean P.director, officer: Chief Executive Officer

SellTue Jan 27

Nolan Sean P.director, officer: Chief Executive Officer

SellTue Jan 27

Latest News

Taysha Gene Therapies to Present New Preclinical Data Supporting Construct Design of TSHA-102 for Rett Syndrome at the ASGCT 2026 Annual MeetingGlobeNewsWire · Mon Apr 27

Company Info

Sector

Healthcare

Industry

Biotechnology

Country

Exchange

—

Beta

1.23

Taysha Gene Therapies, Inc., a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN1 disease; TSHA-118 for the treatment of CLN1 disease; TSHA-105 foe the treatment of for SLC13A5 Deficiency; and TSHA-101 for the treatment of GM2 gangliosidosis. Taysha Gene Therapies, Inc. has a strategic partnership with The University of Texas Southwestern Medical Center to develop and commercialize transformative gene therapy treatments. The company was incorporated in 2019 and is based in Dallas, Texas.

Peers

OCS